Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Some mechanism/ingredient descriptions and general safety themes are broadly consistent with the provided label excerpts (e.g., contraindication in pregnancy, local adverse reactions). However, key label-required safety messaging is missing or misstated (notably treatment indication/target population details, and pregnancy precautions framed inaccurately as 'typically drives' precautions). Several claims are partially unsupported because the label excerpts do not substantiate them as stated.
Category Scores
Accurate Statements
Duobrii is a topical prescription medication that combines two active ingredients: halobetasol propionate and tazarotene.
Consistent with provided label name/actives: DUOBRII (halobetasol propionate and tazarotene) Lotion.
Halobetasol propionate helps calm inflammatory skin changes.
Label excerpt states corticosteroids play a role in inflammation (precise MOA for plaque psoriasis unknown).
Tazarotene affects skin cell differentiation and turnover.
The provided label excerpt describes tazarotene as a retinoid prodrug converted to tazarotenic acid that binds retinoic acid receptors and modifies gene expression; it does not specifically mention 'differentiation and turnover' in the excerpt, but the retinoid/gene expression MOA is directionally aligned.
Used together, halobetasol propionate and tazarotene target inflammation from the steroid and underlying abnormal skin processes from the retinoid.
Supports corticosteroids’ role in inflammation and tazarotene’s MOA in gene expression; label also states clinical significance/precise mechanism in plaque psoriasis is unknown.
Unsupported Statements
Duobrii is used for skin conditions in which a clinician prescribes a combination of halobetasol propionate (a potent corticosteroid) and tazarotene.
The label excerpt provided specifies indication as topical treatment of plaque psoriasis in adults; it does not support the broader phrasing 'skin conditions' or the idea that it is used whenever a clinician prescribes the combination.
Tazarotene is the ingredient in this combination that typically drives pregnancy-related precautions in topical retinoid therapies.
The label excerpt states DUOBRII is contraindicated in pregnancy and explains retinoid/teratogenicity; it does not state that pregnancy-related precautions are 'typically driven' by tazarotene versus the combination or by 'topical retinoid therapies' generally.
Retinoids like tazarotene can cause dryness, redness, or irritation.
The provided label excerpt discusses local adverse reactions (e.g., atrophy, striae, telangiectasias, folliculitis, contact dermatitis) and 'avoid use on eczematous skin, as it may cause severe irritation,' but it does not specifically list 'dryness, redness, or irritation' as a tazarotene/retinoid effect in these excerpts.
Potent steroids can raise safety concerns if used incorrectly or over large areas or long periods.
The provided excerpts do not describe duration/area-related safety concerns or 'used incorrectly' messaging for halobetasol; only pregnancy contraindication and certain local adverse reactions are shown.
Contradictions
Low
AI Statement
Tazarotene is the ingredient in this combination that typically drives pregnancy-related precautions in topical retinoid therapies.
Label Reference
Label excerpt: DUOBRII may cause fetal harm and is contraindicated in pregnancy; advises pregnancy test within 2 weeks, initiate during a menstrual period, and use effective contraception. It attributes fetal harm to retinoid pharmacology and potential systemic absorption of DUOBRII, but does not support the 'typically drives' claim.
Important Omissions
Approved indication specificity: topical treatment of plaque psoriasis in adults (not just 'skin conditions').
Importance:
Moderate
Pregnancy risk mitigation details required by label: obtain pregnancy test within 2 weeks prior; initiate therapy during a menstrual period; use effective contraception during treatment; DUOBRII is contraindicated in pregnancy.
Importance:
Moderate
Local adverse reactions list and management: atrophy, striae, telangiectasias, folliculitis, contact dermatitis; discontinue at least until skin integrity restored; do not resume if allergic contact dermatitis is identified; avoid use on eczematous skin due to severe irritation.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Pregnancy-related counseling/precautions and the exact labeled contraindication management steps are not accurately or completely reflected in the provided AI claims. Some adverse reaction descriptors are generalized beyond the excerpts, and important label-specific local adverse reaction management guidance is omitted.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Pregnancy precautions and adverse reaction details are not provided with label-specific accuracy; the indication is described too broadly and missing the adult plaque psoriasis specificity.
Suggested Improvement
Restrict indication language to 'topical treatment of plaque psoriasis in adults' and align pregnancy-related statements to the label requirements (contraindication in pregnancy; pregnancy test within 2 weeks prior; initiate during a menstrual period; effective contraception during treatment). Replace generalized dryness/redness/irritation and steroid safety-duration statements with label-listed local adverse reactions and the label’s explicit discontinuation/avoidance instructions.